ExodusPoint Capital Management LP Cuts Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG)

ExodusPoint Capital Management LP cut its position in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 66.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 188,430 shares of the company's stock after selling 366,528 shares during the period. ExodusPoint Capital Management LP owned about 0.16% of 10x Genomics worth $2,706,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in the company. Signaturefd LLC increased its stake in shares of 10x Genomics by 424.6% during the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company's stock valued at $26,000 after buying an additional 1,452 shares during the period. Blue Trust Inc. increased its position in 10x Genomics by 73.1% during the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock valued at $44,000 after purchasing an additional 1,299 shares during the period. Sound Income Strategies LLC increased its position in 10x Genomics by 65.2% during the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock valued at $48,000 after purchasing an additional 1,330 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of 10x Genomics in the 4th quarter valued at about $52,000. Finally, SRS Capital Advisors Inc. lifted its position in shares of 10x Genomics by 817.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company's stock worth $70,000 after purchasing an additional 4,324 shares during the period. 84.68% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

TXG has been the subject of a number of recent research reports. Leerink Partnrs downgraded shares of 10x Genomics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 13th. Canaccord Genuity Group reduced their price target on 10x Genomics from $20.00 to $18.00 and set a "buy" rating for the company in a research report on Thursday, February 13th. Citigroup dropped their price objective on 10x Genomics from $20.00 to $15.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. Barclays reduced their target price on shares of 10x Genomics from $15.00 to $12.00 and set an "overweight" rating for the company in a report on Thursday. Finally, Leerink Partners lowered shares of 10x Genomics from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $25.00 to $12.00 in a research report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, 10x Genomics currently has an average rating of "Hold" and a consensus target price of $19.79.

Insider Transactions at 10x Genomics

In other 10x Genomics news, Director Alan Mateo purchased 40,000 shares of the stock in a transaction on Friday, February 21st. The shares were bought at an average cost of $11.14 per share, with a total value of $445,600.00. Following the completion of the acquisition, the director now owns 61,691 shares in the company, valued at $687,237.74. This trade represents a 184.41 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Serge Saxonov sold 5,092 shares of 10x Genomics stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $11.07, for a total value of $56,368.44. Following the transaction, the chief executive officer now owns 879,482 shares of the company's stock, valued at $9,735,865.74. The trade was a 0.58 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 10.03% of the company's stock.

10x Genomics Trading Up 4.0 %

Shares of NASDAQ TXG traded up $0.31 during midday trading on Friday, reaching $8.01. The company had a trading volume of 3,349,046 shares, compared to its average volume of 2,165,375. 10x Genomics, Inc. has a 1 year low of $6.78 and a 1 year high of $36.15. The business's 50-day simple moving average is $10.44 and its 200 day simple moving average is $13.96. The stock has a market cap of $979.64 million, a P/E ratio of -5.27 and a beta of 2.01.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. Analysts predict that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.